Breaking News Instant updates and real-time market news.

BSX

Boston Scientific

$37.31

-0.01 (-0.03%)

, ABBV

AbbVie

$79.83

0.37 (0.47%)

08:57
05/21/19
05/21
08:57
05/21/19
08:57

UBS to hold a conference

Global Healthcare Conference will be held in New York on May 20-22 with webcasted company presentations to begin on May 21 at 8 am; not all company presentations may be webcasted. Webcast Link

BSX

Boston Scientific

$37.31

-0.01 (-0.03%)

ABBV

AbbVie

$79.83

0.37 (0.47%)

WST

West Pharmaceutical

$117.38

1.085 (0.93%)

VAR

Varian Medical

$130.48

-0.26 (-0.20%)

LLY

Eli Lilly

$116.24

0.17 (0.15%)

MYGN

Myriad Genetics

$25.21

-0.77 (-2.96%)

CNCE

Concert Pharmaceuticals

$10.54

-0.05 (-0.47%)

EXEL

Exelixis

$19.61

0.29 (1.50%)

RGEN

Repligen

$67.29

0.06 (0.09%)

SGRY

Surgery Partners

$9.99

-0.11 (-1.09%)

CRSP

Crispr Therapeutics

$37.61

-1.16 (-2.99%)

ABT

Abbott

$75.77

-0.2 (-0.26%)

FLDM

Fluidigm

$12.14

0.42 (3.58%)

THC

Tenet

$21.45

0.59 (2.83%)

MTD

Mettler-Toledo

$716.32

-9.89 (-1.36%)

LNTH

Lantheus

$23.96

-0.29 (-1.20%)

MMSI

Merit Medical

$53.97

-0.9 (-1.64%)

GTHX

G1 Therapeutics

$22.57

-0.04 (-0.18%)

AMGN

Amgen

$168.36

-1.5 (-0.88%)

EXAS

Exact Sciences

$96.03

-0.14 (-0.15%)

BMY

Bristol-Myers

$46.29

-0.55 (-1.17%)

DGX

Quest Diagnostics

$97.08

-0.16 (-0.16%)

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 21

    May

  • 22

    May

  • 23

    May

  • 24

    May

  • 28

    May

  • 29

    May

  • 29

    May

  • 29

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 07

    Jun

  • 12

    Jun

  • 13

    Jun

  • 23

    Jun

  • 26

    Jun

  • 30

    Jul

  • 06

    Aug

  • 18

    Sep

  • 19

    Sep

  • 13

    Nov

BSX Boston Scientific
$37.31

-0.01 (-0.03%)

05/13/19
EVER
05/13/19
UPGRADE
EVER
Outperform
Boston Scientific upgraded to Outperform from In Line at Evercore ISI
04/23/19
PIPR
04/23/19
NO CHANGE
Target $42
PIPR
Overweight
Boston Scientific Lotus approval may accelerate share gains, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien kept his Overweight rating and $42 price target on Boston Scientific after its "long anticipated" FDA approval of Lotus Edge transcatheter aortic valve replacement, or TAVR, product. The analyst believes that with the combination of differentiated features and the "buzz at previous medical conferences" about the relaunch may accelerate the company's market share capture in the TAVR space. O'Brien calls today's news a "strong positive" for the stock given the "recent transvaginal surgical mesh notice and paclitaxel concerns."
04/16/19
WELS
04/16/19
NO CHANGE
WELS
Boston Scientific mesh sales impacted by FDA recall about $25M, says Wells Fargo
Wells Fargo analyst Larry Biegelsen says that Boston Scientific has informed him that total mesh sales are about $100M and that the products impacted by the FDA recall represent a subset of those sales or about $25M or 0.3% of total sales. The firm had previously stated that the mesh sales impacted by the FDA recall were about $100M in 2018. Biegelsen notes that the lower figure should be "more manageable" for the company. According to the analyst, Boston Scientific is surprised and disappointed by the FDA's decision, which impacts Uphold LITE Vaginal Support System and the Xenform Soft Tissue Repair Matrix for pelvic organ prolapse.
05/13/19
05/13/19
UPGRADE
Target $42.5

Outperform
Boston Scientific upgraded to Outperform at Evercore ISI on revenue growth
As previously reported, Evercore ISI analyst Vijay Kumar upgraded Boston Scientific to Outperform and raised his price target to $42.50 from $39. The analyst says that the "healthy skepticism" toward his outlook for the company's back half revenue growth potential "creates an opportunity", stating that the worst case scenario of Boston Scientific's paclitaxel coated devices being pulled from market is off the table. Instead, Kumar believes that the company can generate 7%-8% revenue growth into FY20 - the highest rate among its peers - while offering a discount valuation.
ABBV AbbVie
$79.83

0.37 (0.47%)

04/28/19
BMOC
04/28/19
UPGRADE
Target $79
BMOC
Market Perform
AbbVie upgraded to Market Perform from Underperform at BMO Capital
BMO Capital analyst Alex Arfaei upgraded AbbVie to Market Perform from Underperform and raised his price target for the shares to $79 from $71. The stock closed Friday up 29c to $79.70. The analyst says his bearish thesis has mostly materialized and that he's now more bullish on Skyrizi and Upa. AbbVie can leverage its rebates to secure superior access in the U.S. and drive "strong" launches, Arfaei tells investors in a research note. He believes after a flat 2019, Skyrizi, Upa, Imbruvica/Venclexta and Orilissa should drive 4%-6% revenue growth during 2020-2022. This should improve sentiment on shares of AbbVie, says the analyst.
04/11/19
EVER
04/11/19
INITIATION
Target $30
EVER
Outperform
Myovant Sciences initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Myovant Sciences (MYOV) with an Outperform rating and a price targets of $30. The analyst says the company's lead program relugolix has been clinically de-risked with near-term pivotal data readouts. Mehrotra is modeling revenues of $944M for the program by 2023 thanks to its "commercial advantage of a one-a-day pill" and the "second-mover leverage of competitor AbbVie's (ABBV) efforts to raise awareness and diagnosis" in woman's health market.
03/26/19
WBLR
03/26/19
UPGRADE
WBLR
Outperform
William Blair upgrades Vertex to Outperform after 'subpar' competitor data
William Blair analyst Y. Katherine Xu upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform on expectations the company's cystic fibrosis franchise will continue dominating after Proteostasis (PTI) reported disappointing triplet data. Proteostasis' triplet efficacy falls short of the high bar set by the Vertex triples, Xu tells investors in a research note. While Proteostasis is starting a Phase II study of the triplet that would include a higher PTI-808 dose and test a longer duration aiming to optimize response with data out around year-end 2019, the chance of it matching or exceeding Vertex triple efficacy is "very low," contends the analyst. With both Galapagos (GLPG)/AbbVie (ABB) and Proteostasis having shown "subpar data," Xu is upgrading Vertex shares to Outperform and raised her fair value estimate for the shares to $222 from $178. The analyst maintains her high probability of success of a Vertex triple combo reaching the cystic fibrosis market at 90% and ascribe peak sales of $10.2B, up from $8.9 billion previously.
05/14/19
LEHM
05/14/19
NO CHANGE
Target $25
LEHM
Overweight
Myovant Sciences selloff overdone after report of relugolix data, says Barclays
Barclays analyst Geoffrey Meacham said he thinks the selloff in shares of Myovant Sciences (MYOV) is overdone after the release of relugolix phase 3 uterine fibroids data. He believes investors are "selling the news" and he still believes relugolix has a comparable profile to AbbVie (ABBV) and Neurocrine's (NBIX) elagolix and will find a place in the market given what he sees as positive data reported this morning, Meacham tells investors. He keeps an Overweight rating and $25 price target on Myovant shares, which are down 26% to $12.67 in early afternoon trading.
WST West Pharmaceutical
$117.38

1.085 (0.93%)

04/23/19
WBLR
04/23/19
INITIATION
WBLR
Outperform
William Blair starts drug packaging play West Pharmaceutical at Outperform
As previously reported, William Blair analyst John Kreger started West Pharmaceutical Services with an Outperform rating, stating that he sees the stock as "an excellent, lower-risk way" to participate in the pharmaceutical industry's shift toward large molecule biologics in injectable dosage forms that need special packaging, delivery, and sterility. He cites three reasons that he views outsourced pharmaceutical packaging as an "attractive, defensive growth industry," namely that drug innovation is trending toward injectable dosage forms; innovation is shifting to smaller clients less likely to have in-house development and manufacturing expertise; and the industry's high regulatory burden makes it hard, and costly, to shift manufacturing once a product is approved. Kreger forecasts West can generate mid- to high single-digit organic revenue growth and low-double-digit earnings growth, he noted.
04/23/19
WBLR
04/23/19
INITIATION
WBLR
Outperform
West Pharmaceutical initiated with an Outperform at William Blair
William Blair analyst John Kreger started West Pharmaceutical Services with an Outperform rating. West offers a packaging and containment play on biologics and injectables, Kreger tells investors in a research note.
05/01/19
JEFF
05/01/19
DOWNGRADE
JEFF
Hold
West Pharmaceutical downgraded to Hold from Buy at Jefferies
05/01/19
JEFF
05/01/19
DOWNGRADE
Target $122
JEFF
Hold
Jefferies downgrades West Pharmaceutical to Hold into slower growth
Jefferies analyst David Windley downgraded West Pharmaceutical to Hold from Buy with an unchanged price target of $122 following the company's Q1 results. Slower growth on "significantly" tougher comps in Q2 and Q3 will bring the stock into a better entry point, Windley tells investors in a research note. The analyst views West Pharmaceutical's risk/reward as balanced at current "peak" valuation levels.
VAR Varian Medical
$130.48

-0.26 (-0.20%)

03/22/19
03/22/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Pearson (PSO) upgraded to Overweight from Neutral at JPMorgan with analyst Daniel Kerven saying the company's business model is improving as its moves from print to digital. 2. Lumentum (LITE) upgraded to Overweight from Neutral at JPMorgan with analyst Samik Chatterjee seeing a "solid" outlook for the company's telecom business amid "strong" growth led by 5G investments and upside to synergy targets relative to recent acquisition of Oclaro. 3. Best Buy (BBY) upgraded to Outperform from Perform at Oppenheimer with analyst Brian Nagel stating the company has undergone a significant transformation under the direction of new senior leadership to one of retail's preeminent omnichannel operators. 4. Varian Medical (VAR) upgraded to Outperform from Neutral at Baird with analyst Jason Bednar saying that with near-term trends sounding healthy, multiple paths are emerging for Varian to sustain upper-single digit plus oncology order growth, and low- to mid-teens EPS growth. 5. Chipotle (CMG) upgraded to Neutral from Underperform at Wedbush with analyst Nick Setyan noting he no longer sees risk to near- and medium-term same-store sales growth and unit-level margin expectations. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
03/22/19
BARD
03/22/19
UPGRADE
BARD
Outperform
Varian Medical upgraded to Outperform from Neutral at Baird
03/22/19
BARD
03/22/19
UPGRADE
Target $162
BARD
Outperform
Varian Medical upgraded to Outperform from Neutral at Baird
Baird analyst Jason Bednar upgraded Varian Medical to Outperform from Neutral and raised his price target to $162 from $127. In a research note to investors, Bednar says that with near-term trends sounding healthy, multiple paths are emerging for Varian to sustain upper-single digit plus oncology order growth, and low- to mid-teens EPS growth looking increasingly likely and sustainable into fiscal 2020 and beyond, he believes Varian is quickly becoming a premium medech grower and a stock that investors can consider a core medtech holding.
04/04/19
BRRR
04/04/19
NO CHANGE
Target $150
BRRR
Outperform
Varian Medical price target raised to $150 from $135 at Barrington
Barrington analyst Michael Petusky raised his price target for Varian Medical Systems to $150 from $135 after the company disclosed the initial preclinical results of its research on ultra-high dose cancer treatment utilizing protons at the American Association for Cancer Research meeting. The analyst views the early results as "encouraging" and adds that order momentum at Varian over the past several months "has been extremely strong." He keeps an Outperform rating on the shares.
LLY Eli Lilly
$116.24

0.17 (0.15%)

04/18/19
PIPR
04/18/19
NO CHANGE
PIPR
Teva gains ground on Amgen in latest migraine survey, says Piper Jaffray
Following of survey of 99 neurologists done by his firm's partner Spherix Global Insights, Piper Jaffray analyst Christopher Raymond maintains an Overweight rating on Amgen (AMGN) and a Neutral rating on Teva Pharmaceutical (TEVA). The migraine survey indicates Eli Lilly's (LLY) Emgality is lagging and that Teva's Ajovy appears to be gaining ground on Amgen's Aimovig across numerous metrics, Raymond tells investors in a research note. While one data point does not a trend make, this move warrants close attention, especially given the increased significance assigned to Aimovig with respect to Amgen sentiment, says the analyst. Raymond, however, remains cautious on Teva shares given the" lack of clarity regarding when/where EBITDA will hit a trough." On the R&D side, the analyst notes that Overweight-rated Alder Biopharmaceuticals' (ALDR) eptinezumab "appears to be particularly top-of-mind among migraine specialists."
04/24/19
04/24/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Eli Lilly (LLY) upgraded to Buy from Hold at Edward Jones. 2. Snap (SNAP) upgraded to In Line from Underperform at Evercore ISI and to Neutral from Underweight at JPMorgan. 3. Best Buy (BBY) upgraded to Buy from Hold at Jefferies with analyst Jonathan Matuszewski saying survey and data work suggest Best Buy's greater push toward services will drive long-term value and customer wallet share. 4. Procter & Gamble (PG) upgraded to Overweight from Equal Weight at Barclays with analyst Lauren Lieberman saying the market is shrugging off Procter & Gamble's 5% organic sales growth in its fiscal Q3, with many investors thinking this is the best it can get. 5. Sonoco (SON) upgraded to Buy from Hold at Argus with analyst David Coleman saying the stock has outperformed over the past 3 months, benefiting from its "accretive acquisitions, favorable pricing, improvements in productivity, and a lower effective tax rate." This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/23/19
EDJN
04/23/19
UPGRADE
EDJN
Buy
Eli Lilly upgraded to Buy from Hold at Edward Jones
Edward Jones analyst Ashtyn Evans upgraded Eli Lilly to Buy from Hold.
04/22/19
BMOC
04/22/19
NO CHANGE
Target $130
BMOC
Outperform
Eli Lilly price target lowered to $130 from $134 at BMO Capital
BMO Capital analyst Alex Arfaei lowered his price target on Eli Lilly to $130, saying the stock has underperformed along with its peers, and the news around its Tanezumab announced last week was "obviously negative". The analyst is keeping his Outperform rating however and believes that risk-reward on Eli Lilly is still "attractive" based on his "higher forecasts for Trulicity, Taltz, and Jardiance", as well as expectations around "improved margins". Arfaei adds that the company's upcoming REWIND data at the American Diabetes Association summit could be the "next major catalyst" for Eli Lilly shares.
MYGN Myriad Genetics
$25.21

-0.77 (-2.96%)

05/14/19
NEED
05/14/19
NO CHANGE
Target $32
NEED
Strong Buy
Myriad Genetics price target lowered to $32 from $41 at Needham
Needham analyst Stephen Unger lowered his price target on Myriad Genetics to $32 after its mixed Q3 results last week, saying that while its earnings grew 35% and Hereditary Cancer revenue grew 4%, GeneSight and Prenatal revenues declined 2.6% y/y and 1.9% sequentially. The analyst is also concerned with pricing and reimbursement "re-emerging" as an issue on expectations of flat Hereditary Cancer revenue and a sequential Q4 decline in Prenatal revenue. Unger maintains a Strong Buy rating on Myriad Genetics given its valuation and the "potential for expanded GeneSight payor coverage."
03/12/19
NEED
03/12/19
NO CHANGE
Target $41
NEED
Strong Buy
Myriad Genetics price target raised to $41 from $37 at Needham
Needham analyst Stephen Unger raised his price target on Myriad Genetics to $41 and kept his Strong Buy rating after meeting with its management last week to discuss the company's short and long term issues and opportunities. The analyst says the discussions have left him "incrementally bullish" on the stock given its "potential for meaningful revenues from expanded commercial payor coverage of GeneSight and Foresight". Unger is also positive on the company's "promising incremental opportunity in melanoma testing through myPath Melanoma".
03/14/19
PIPR
03/14/19
NO CHANGE
Target $47
PIPR
Overweight
Myriad Genetics on cusp of positive news events, says Piper Jaffray
After hosting investor meetings with management, Piper Jaffray analyst William Quirk believes Myriad Genetics (MGN) is "on the cusp of several positive news events." Management is optimistic that they could get a draft local coverage determinations for expanded GeneSight coverage by Medicare, Quirk tells investors in a research note. He expects visibility on this by late March. Further, the analyst believes Counsyl's April 1 in-network status with UnitedHealth (UNH) could lead to $6M-$7M upside to his current Q4 estimates. Quirk reiterates an Overweight rating on Myriad Genetics with a $47 price target.
04/01/19
PIPR
04/01/19
NO CHANGE
PIPR
Overweight
Myriad traded lower on 'minor' United Healthcare change, says Piper Jaffray
Shares of Myriad Genetics closed Friday down 4% after United Healthcare (UNH) added a Current Procedural Terminology code and simplified the coverage rationale on its existing medical policy for pharmacogenetics, Piper Jaffray analyst William Quirk tells investors in a research note. The updated policy does not include a review of the Genesight dossier/Guided study, says the analyst. He views the change at United Healthcare as "minor" and keeps an Overweight rating on Myriad Genetics. Quirk continues to look for positive Genesight coverage.
CNCE Concert Pharmaceuticals
$10.54

-0.05 (-0.47%)

02/07/19
MZHO
02/07/19
NO CHANGE
Target $26
MZHO
Buy
Concert Pharmaceuticals undervalued ahead of 2019 catalysts, says Mizuho
After holding investor meetings with management, Mizuho analyst Difei Yang says shares of Concert Pharmaceuticals are undervalued ahead of important catalysts in 2019. Catalysts include a Patent Trial and Appeal Board decision related to the CTP-543 patent litigation expected by April 9, top-line data from the CTP-543 12mg cohort in Q3, Phase 3 data in Alzheimer's Agitation possibly in Q2, and Phase 1 data from CTP-692 in schizophrenia in the first half of 2019, Yang tells investors in a research note. The analyst sees "strong potential" in CTP-543, regardless of the intellectual property litigation outcome, and believes the asset has potential to be first-to-market for the treatment of alopecia areata. She keeps a Buy rating on Concert Pharmaceuticals with a $26 price target.
04/09/19
STFL
04/09/19
NO CHANGE
Target $18
STFL
Buy
Concert Pharmaceuticals price target lowered to $18 from $27 at Stifel
Stifel analyst Adam Walsh said the USPTO ruling that the claims of Concert Pharmaceuticals' patent covering composition of matter for CTP-543 is not patentable significantly reduces his expected duration of market exclusivity upon approval to 5.5 years from his previous assumption of protection out to 2033. Given this lowered exclusivity assumption, he cut his price target on Concert shares to $18 from $27. However, Walsh keeps a Buy rating on the stock and said the recent selloff seems overdone given his view on several near-term potential catalysts.
04/09/19
JMPS
04/09/19
NO CHANGE
Target $20
JMPS
Outperform
Concert Pharmaceuticals price target lowered to $20 from $26 at JMP Securities
JMP Securities analyst Liisa Bayko lowered her price target on Concert Pharmaceuticals (CNCE) shares to $20 from $26 after USPTO ruled in favor of Incyte (INCY) that claims in Concert's '149 patent are not patentable. Concert said it will appeal the decision, but Bayko thinks a reversal of the PTAB decision is unlikely. She now assumes only 5.5 years of exclusivity for CTP-543, continues to recommend Concert, stating that she sees a $1B opportunity in alopecia areata given the size, unmet need, and competitive landscape. Bayko keeps an Outperform rating on Concert shares.
12/18/18
MZHO
12/18/18
NO CHANGE
Target $26
MZHO
Buy
Concert remains best-in-class after Aclaris data, says Mizuho
Mizuho analyst Difei Yang reiterates a Buy rating on Concert Pharmaceuticals (CNCE) after competitor Aclaris Therapeutics (ACRS) reported data from its topical Janus kinase 1/3 inhibitor for the treatment of alopecia areata. While a number of patients were responders in the eyebrow and alopecia totalis/alopecia universalis Phase 2 trials, improvements on Severity of Alopecia Tool scores were not disclosed and a few patients withdrew from the studies, Yang tells investors in a research note. The analyst sees Concert Pharmaceuticals' CTP-543 as best-in-class and more competitive for the treatment of moderate/severe alopecia areata. Yang keeps a $26 price target on Concert shares.
EXEL Exelixis
$19.61

0.29 (1.50%)

02/25/19
COWN
02/25/19
NO CHANGE
COWN
Exelixis coverage transferred with an Outperform at Cowen
Cowen analyst Yaron Werber assumed coverage of Exelixis with an Outperform rating and $29 price target. Werber noted that, "after strong growth, Cabometyx is facing intense competition that may pressure sales," but the analyst anticipates positive Phase 3 data from CHECKMATE-9ER in the second half of 2019 re-accelerating growth. Werber also believes that "recent strong bids for oncology companies may put Exelixis at play for takeout."
03/01/19
PIPR
03/01/19
NO CHANGE
Target $48
PIPR
Overweight
Exelixis price target raised to $48 from $26 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Exelixis to $48 after taking a closer look at the company's bottom-line including breaking out non-cash expenses. The analyst projects U.S. Cabometyx sales to grow from $600M in 2018, to $826M in 2019 and $1.07B in 2020. Factoring in a 22% projected tax rate, he forecasts GAAP net income of $300M, or 95c per diluted share, in 2019 to increase to $375M or $1.17, in 2020. Backing out non-cash stock comp and federal taxes, the analyst projects Non-GAAP net income to grow from $431M or $1.37 per diluted share in 2019 to $532M or $1.66 in 2020. Tenthoff reiterates an Overweight rating on Exelixis.
03/18/19
MSCO
03/18/19
UPGRADE
MSCO
Equal Weight
Exelixis upgraded to Equal Weight from Underweight at Morgan Stanley
03/18/19
MSCO
03/18/19
UPGRADE
Target $28
MSCO
Equal Weight
Morgan Stanley sees limited downside risk for Exelixis, upgrades to Equal Weight
As previously reported, Morgan Stanley analyst Jeffrey Hung upgraded Exelixis to Equal Weight from Underweight, citing his view there is limited downside risk for the stock ahead of the cabozantinib/nivolumab data from CheckMate 9ER later this year. Additionally, cabozantinib scripts are looking better in 2019 and Hung sees multiple ways this trend could continue, he tells investors. Hung raised his price target on Exelixis shares to $28 from $20.
RGEN Repligen
$67.29

0.06 (0.09%)

12/17/18
12/17/18
UPGRADE
Target $65

Buy
Follow-up: Repligen upgraded to Buy on valuation at CL King
As previously reported, CL King upgraded Repligen to Buy from Neutral with a $65 price target. Analyst David Westenberg said shares are now trading at a "reasonable" valuation with near-term drivers looking positive.
11/05/18
HCWC
11/05/18
NO CHANGE
Target $60
HCWC
Neutral
Repligen price target raised to $60 from $49 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Repligen to $60 but reiterates a Neutral rating on the name. Solid execution produced a "modest beat" in Q3, but the stock reaction may have been overdone, Selvaraju tells investors in a research note. He believes the stock "still looks expensive."
11/12/18
KING
11/12/18
DOWNGRADE
KING
Neutral
Repligen downgraded to Neutral from Buy at CL King
CL King analyst David Westenberg downgraded Repligen to Neutral from Buy.
12/17/18
KING
12/17/18
UPGRADE
KING
Buy
Repligen upgraded to Buy from Neutral at CL King
SGRY Surgery Partners
$9.99

-0.11 (-1.09%)

11/15/18
UBSW
11/15/18
INITIATION
UBSW
HCA Healthcare, Encompass Health, Universal Health initiated with Buy at UBS
UBS analyst Whit Mayo launched coverage of Healthcare Facilities with a broader research note titled "Navigating an Evolving Landscape - Who Will Be Left?". The analyst is most bullish on stocks that "discount the perceived secular sector headwinds" such as Buy-rated HCA Healthcare (HCA), Encompass Health (EHC), and Universal Health (UHS), adding that investors also under-appreciate the accelerating free-cash flow profiles of these companies. Mayo differentiates HCA Healthcare based on its 0% correlation in national hospital utilization trends against public results. The analyst is also bullish on LHC Group (LHCG), stating that its same-property admission growth projections are higher than the rest. Mayo rates Community Health Systems (CYH), DaVita (DVA), and Mednax (MD) at a Sell with a bearish view of dialysis, births, and inpatient surgery end-markets. The analyst sees Community Health Systems same-property volume trend at a relatively low rate. Mayo also gives Acadia (ACHC), Amedisys (AMED), Surgery Partners (SGRY), and Tenet (THC) a Neutral rating as part of this research note based on their relative valuation as a factor of same-property volume growth.
09/18/18
BOFA
09/18/18
UPGRADE
BOFA
Buy
Surgery Partners upgraded to Buy from Neutral at BofA/Merrill
09/18/18
BOFA
09/18/18
UPGRADE
Target $20
BOFA
Buy
Surgery Partners upgraded to Buy on volume turnaround at BofA/Merrill
As previously reported, BofA/Merrill upgraded Surgery Partners to Buy from Neutral and maintained a $20 price target. Analyst Kevin Fischbeck believes Surgery Partners' volume turnaround is near an inflection point and expects growth to improve through 2018 and 2019.
11/15/18
UBSW
11/15/18
INITIATION
Target $15
UBSW
Neutral
Surgery Partners initiated with a Neutral at UBS
UBS analyst Whit Mayo initiated Surgery Partners with a Neutral rating and a price target of $15.
CRSP Crispr Therapeutics
$37.61

-1.16 (-2.99%)

04/11/19
EVER
04/11/19
INITIATION
Target $46
EVER
Outperform
Crispr Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Crispr Therapeutics with an Outperform rating and a price targets of $46. The analyst says the company's ex vivo gene therapy gives it a low risk path to market while it continues to refine its delivery systems required for in vivo editing. Mehrotra also cites Crispr's potential to have several programs in clinic in 2019-2020, along with strong partnerships and clinical execution that "could lead to significant near term clinical news flow."
04/16/19
PIPR
04/16/19
NO CHANGE
Target $75
PIPR
Overweight
Piper reiterates $75 target for Crispr after CTX001 gets Fast Track
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Crispr Therapeutics after the company and partner Vertex (VRTX) announced Fast Track Designation for CTX001 to treat transfusion-dependent beta thalassemia. The analyst believes Crispr's ex vivo approach and biological rational of targeting fetal hemoglobin "de-risk and differentiate" CTX001 from other gene editing players. And he continues to think that first-in-man CTX001 data this year "will serve as an important driver" for Crispr and the gene editing field. Tenthoff says Crispr Therapeutics remains a top for 2019.
04/22/19
BTIG
04/22/19
NO CHANGE
BTIG
Buy
BTIG raises price targets on Editas Medicine, CRISPR Therapeutics
BTIG analyst Amanda Murphy raised her price target on Buy-rated Editas Medicine (EDIT) to $33 from $30 and CRISPR Therapeutics (CRSP) to $49 from $43 as part of her first installment of a broader research note analyzing hiring trends in the gene therapy space. The analyst notes that the latter is "aggressively adding process development/CMC/Tech capabilities in cell therapy, including late stage process development resources", which may suggest that the company is "farther along" in the development of CTX110. Murphy also observes that Editas Medicine appears to be "shifting focus to engineered stem cell therapy while still investing in allo CAR-T and potentially new in vivo indications and delivery vectors."
04/30/19
PIPR
04/30/19
NO CHANGE
Target $75
PIPR
Overweight
Crispr Therapeutics remains a top pick for 2019 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff says Crispr Therapeutics remains a top pick for 2019 following the company's Q1 results. The company has a cash position of $456M its Phase I/II study of CTX001 in transfusion-dependent beta thalassemia is "on-going," which suggests the first patient has successfully engrafted representing a "significant milestone," Tenthoff tells investors in a research note. He expects "first-in-man data" from both Phase I/II studies later this year to "serve as a major driver" and reiterates an Overweight rating on the stock with a $75 price target.
ABT Abbott
$75.77

-0.2 (-0.26%)

04/03/19
JPMS
04/03/19
NO CHANGE
Target $175
JPMS
Overweight
JPMorgan remains 'very bullish' on DexCom despite Libre 2.0 uncertainty
The latest DexCom (DXCM) controversy is "whirling speculation" around Abbott's (ABT) Libre 2.0 launch, JPMorgan analyst Robbie Marcus tells investors in a research note. The analyst keeps an Overweight rating on DexCom shares with a $175 price target but expects uncertainty over Libre 2.0 to remain an overhang until it receives U.S. approval. However, he remains "very bullish" on the shares and sees "significant upside" to 2019 estimates. DexComis the best positioned in diabetes longer-term, Marcus contends.
04/29/19
PIPR
04/29/19
NO CHANGE
Target $165
PIPR
Overweight
Piper reiterates Overweight on DexCom after 'robust' teen survey results
There were 8,042 responses to Piper Jaffray's teen survey in February and March, of which 1,707 have diabetes or a member of their household does, analyst JP McKim tells investors in a research note. The survey implies underlying continuous glucose monitoring market growth of close to 58%, says the analyst. Abbott (ABT) reported 70% Libre growth in Q1 and DexCom (DXCM) reports May 1, McKim points out. He expects "continued strong growth" from DexCom following the "robust" survey results and reiterates an Overweight rating on the shares with a $165 price target.
04/18/19
LSCM
04/18/19
NO CHANGE
Target $100
LSCM
Buy
Investors should buy into Tandem Diabetes 'fire sale,' says Lake Street
Lake Street analyst Brooks O'Neil attributes the recent selloff in shares of Tandem Diabetes (TNDM) to investor fears related to the potential implications of "Medicare For All." Yesterday, the decline also appeared to "draw fuel from the strong growth" Abbott (ABT) reported for its Libre glucose monitor for diabetics, O'Neil tells investors in a research note titled "Fire Sale. Should You Buy? Yes. There Is No Fire. Affirm BUY, $100 PT." The analyst doubts the healthcare system will be changed significantly and on Libre, he says, "We're sorry, but we believe investors are either badly confused or just plain wrong." Abbott offers a low-cost version of the monitoring system but does not compete in any way with Tandem in its pump market, says the analyst. Rather, O'Neil thinks there are "potentially significant positives" for Tandem Diabetes related to the "enormous success" of Abbott's Libre franchise. The analyst sees an "extraordinarily positive" outlook for Tandem Diabetes and recommends buying the shares on the recent pullback. He affirms a Buy rating on the shares with a $100 price target.
04/15/19
RBCM
04/15/19
NO CHANGE
Target $82
RBCM
Sector Perform
Abbott price target raised to $82 from $77 at RBC Capital
RBC Capital analyst Brandon Henry raised his price target on Abbott to $82 ahead of its Q1 results, saying the "pattern of revenue growth" seen last year should continue this quarter as Core Laboratory, Electrophysiology, Structural Heart, and Diabetes Care product categories "lead the way." The analyst also expects Abbott's organic revenue growth in the Medical Devices segment to come at the high end of guidance, adding that while his new price target implies a multiple of 22.5-times vs. peer group's 21-times, he believes that the company's growth profile justifies the valuation premium. Henry recommends that investors buy the stock on "any weakness".
FLDM Fluidigm
$12.14

0.42 (3.58%)

03/13/19
BTIG
03/13/19
INITIATION
Target $15
BTIG
Buy
Fluidigm initiated with a Buy at BTIG
BTIG analyst Sung Ji Nam started Fluidigm with a Buy rating and $15 price target. The company's mass cytometry product line is one of the "few emerging, highly differentiated" technology platforms in the life science tools industry providing "unprecedented and potentially revolutionary insights" for life science research, biopharma drug development, and precision medicine, Ji Nam tells investors in a research note. Further, the analyst believes Fluidigm is at an inflection point of sustainably reaccelerating its sales growth.
03/14/19
03/14/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Apple (AAPL) initiated with an Outperform at Cowen. 2. Fluidigm (FLDM) initiated with a Buy at BTIG. 3. Kala Pharmaceuticals (KALA) initiated with a Buy at Jefferies. 4. PLx Pharma (PLXP) initiated with an Outperform at JMP Securities. 5. Walker & Dunlop (WD) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/03/19
PIPR
05/03/19
NO CHANGE
Target $16
PIPR
Overweight
Fluidigm price target raised to $16 from $14 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Fluidigm to $16 from $14 and reiterates an Overweight rating on the shares following the company's Q1 results. Following the relatively in-line quarter, Q2 revenue guidance is below consensus, but cash usage is much better than expectations, Quirk tells investors in a research note. The analyst believes Fluidigm is executing on its Mass Cytometry opportunity and that the company "remains poised for upside in future quarters."
03/15/19
UBSW
03/15/19
INITIATION
Target $14
UBSW
Neutral
Fluidigm initiated with a Neutral at UBS
UBS analyst Daniel Brennan started Fluidigm with a Neutral rating and $14 price target. After the 100% rally since the December 2018 secondary, and 60% rise year-to-date, the stock is fairly valued, Brennan tells investors in a research note. The analyst prefers to wait for a better entry point.
THC Tenet
$21.45

0.59 (2.83%)

04/17/19
SPHN
04/17/19
NO CHANGE
SPHN
Issues facing healthcare sector now 'modest' compared to 2008-10, says Stephens
Stephens analyst Scott Fidel noted that the managed care group has sharply underperformed the S&P 500 over the last month amid "political rhetoric" around point-of-sale drug rebates and Medicare for all policy proposals, though he believes the issues facing the sector right now "seem modest in comparison" to the "dark days of 2008-2010." While recent Medicare for all proposals have rattled investors, "they will face enormous uphill battles," Fidel tells investors. Hospital stocks have outperformed MCOs year-to-date, but the group declined about 9% yesterday and underperformed the MCO group, which Fidel attributes to acknowledgement by industry bellwether UnitedHealth (UNH) of the significant disruptive nature of Medicare for all, which may have sparked additional fears, as well as one less calendar day being called out by UnitedHealth as benefiting Q1 MLRs and Johnson & Johnson's (JNJ) earnings call commentary on declining sequential hospital admissions from Q4. Publicly traded companies in the hospital space include Community Health (CYH), HCA Healthcare (HCA), LifePoint (LPNT), Tenet (THC) and Universal Health (UHS). Publicly traded companies in the managed care space include Anthem (ANTM), CVS Health (CVS), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH) and WellCare (WCG).
02/27/19
RAJA
02/27/19
NO CHANGE
Target $47
RAJA
Outperform
Tenet price target raised to $47 from $37 at Raymond James
01/14/19
SPHN
01/14/19
INITIATION
Target $23
SPHN
Equal Weight
Tenet initiated with an Equal Weight at Stephens
Stephens analyst Scott Fidel initiated coverage of 11 Managed Care and Healthcare Facilities stocks, telling investors that overall he is constructive on managed care and selective on hospitals. He started Tenet with an Equal Weight rating and $23 price target, stating that the market's increased volatility could further complicate its efforts to sell Conifer at an attractive valuation. The persistent underperformance of the hospital segment and ongoing divestiture program make it hard to forecast more than low-single digit annual revenue and EBITDA growth, said Fidel.
05/01/19
RHCO
05/01/19
NO CHANGE
Target $27
RHCO
Hold
Tenet price target lowered to $27 from $34 at SunTrust
SunTrust analyst David MacDonald lowered his price target on Tenet to $27 to reflect lower market multiples in the industry. The analyst also keeps his Hold rating on the stock, saying that while the company's Q1 results saw solid volume trends and progress on the management's efficiency initiatives, he sees "continued operational execution and free cash flow generation" as key.
MTD Mettler-Toledo
$716.32

-9.89 (-1.36%)

01/03/19
01/03/19
DOWNGRADE

Underperform
Mettler-Toledo downgraded to Underperform at Evercore ISI
As previously reported, Evercore ISI downgraded Mettler-Toledo to Underperform from In Line. Analyst Ross Muken sees downward pressure to core growth given outsized exposure to Industrial, capex, and China.
01/03/19
BOFA
01/03/19
DOWNGRADE
Target $600
BOFA
Neutral
Mettler-Toledo downgraded to Neutral on slowing global growth at BofA/Merrill
As previously reported, BofA/Merrill downgraded Mettler-Toledo to Neutral from Buy. Analyst Derik de Bruin sees little room for multiple expansion given concerns regarding slowing global growth and lingering trade issues, and lowered its price target to $600 from $645
01/03/19
BOFA
01/03/19
DOWNGRADE
BOFA
Neutral
Mettler-Toledo downgraded to Neutral from Buy at BofA/Merrill
01/03/19
EVER
01/03/19
DOWNGRADE
EVER
Underperform
Mettler-Toledo downgraded to Underperform from In Line at Evercore ISI
LNTH Lantheus
$23.96

-0.29 (-1.20%)

08/02/18
WELS
08/02/18
NO CHANGE
Target $20
WELS
Outperform
Lantheus price target lowered to $20 from $26 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen lowered his price target for Lantheus to $20 from $26 after the company reported Q2 revenue that missed Street expectations due to a TechneLite supply shortage but modestly beat consensus on adjusted EBITDA. The analyst reiterates an Outperform rating on the shares.
06/18/18
JEFF
06/18/18
NO CHANGE
Target $21
JEFF
Buy
Lantheus position in moly more secure than stock suggests, says Jefferies
A presentation by new molybdenum-99 supplier SHINE Medical Technologies adds more support to Lantheus' (LNTH) position in the market being more secure than the current stock price reflects, Jefferies analyst Raj Denhoy tells investors in a research note. SHINE expects to bring production online in 2021, with Lantheus already contracted to use its molybdenum-99, the analyst adds. He believes the market is "vastly overestimating" the threat from new entrants and "vastly underappreciating" the company's "hold on this market." Denhoy sees little chance of BWX Technologies (BWXT) gaining significant traction given the manufacturing and regulatory challenges in bringing a generator to market. He keeps a Buy rating on Lantheus with a $21 price target.
MMSI Merit Medical
$53.97

-0.9 (-1.64%)

04/24/19
PIPR
04/24/19
NO CHANGE
Target $75
PIPR
Overweight
Piper calls Merit Medical a must own name after Q1 beat
After a "robust" start to 2019, Merit Medical Systems is a mid-cap name that investors need to own, Piper Jaffray analyst Matt O'Brien writes in a research note. He believes the company can deliver some of the best top- and bottom-line growth in med tech in the coming years. Revenue from the recently completed Cianna acquisition helped deliver some of the revenue upside in Q1, but the organic growth in the business remains strong, says O'Brien. He reiterates an Overweight rating on Merit Medical with a $75 price target and says the stock remains his favorite mid-cap name.
03/25/19
PIPR
03/25/19
NO CHANGE
PIPR
Piper sees six 'quality' Med Tech names whose stocks haven't rallied
Medical Technology stocks have rebounded quickly in Q1 following a challenging Q4 of 2018 as the combination of solid year-end results and compelling outlooks for next year have led investors back into the names, Piper Jaffray analyst Matt O'Brien tells investors in a research note. The analyst, however, has identified six "quality" names that have not participated in the Q1 share appreciation, "despite consistently delivering beat-and-raises." The basket of stocks include Abiomed (ABMD), Merit Medical (MMSI), AtriCure (ATRC), Neuronetics (STIM), SeaSpine (SPNE) and Nuvectra (NVTR).
02/11/19
PIPR
02/11/19
NO CHANGE
Target $75
PIPR
Overweight
Piper sees 2018 deals pushing Merit Medical shares 'much higher'
Merit Medical Systems executed four transactions, including one partnership with NinePoint, in 2018, representing capital deployed of approximately $380M, or 13% of its market capitalization, Piper Jaffray analyst Matt O'Brien tells investors in a research note. The analyst says Piper is "big fans" of the deals, with Cianna his favorite given the revenue growth outlook, along with the earnings power it could bring. Collectively he believes the acquired assets will add nearly 200 basis points to Merit Medical's organic revenue growth in 2020 and drive earnings above consensus. This will become clearer to investors in the coming quarters, "pushing shares much higher compared to current levels," says O'Brien. He keeps an Overweight rating on Merit Medical Systems with a $75 price target.
12/18/18
PIPR
12/18/18
NO CHANGE
PIPR
Piper lays out top Medical Technology picks heading into 2019
Piper Jaffray analyst Matt O'Brien tells investors to hold onto Medical Technology stocks into 2019. Multiples are unlikely to increase meaningfully next year, but they should hold given the continued solid fundamentals and strong new product cycles, O'Brien tells investors in a research note after taking a close look at the Med Tech sector. He believes Align Technology (ALGN), Inogen (INGN) and Nuvectra (NVTR) "could provide considerable alpha to investors willing to step up to the plate and buy now." Secondly, the analyst thinks Intuitive Surgical (ISRG) and Merit Medical (MMSI) "could provide a defensive bet in volatile markets."
GTHX G1 Therapeutics
$22.57

-0.04 (-0.18%)

02/07/19
RILY
02/07/19
INITIATION
Target $55
RILY
Buy
B. Riley FBR starts G1 Therapeutics with Buy rating, $55 price target
B. Riley FBR analyst Harshita Polishetty initiated coverage of G1 Therapeutics with a Buy rating and $55 price target. G1's lead candidate, trilaciclib, has the potential to address myelotoxicity and improve overall survival in chemotherapy-associated treatment regimens, Polishetty tells investors in a research note. Further, Lerociclib, although fourth to market, demonstrates potential to be best in class given its clean safety profile thus far adds the analyst. She also believes G1T48 allows for competitive pricing when both lerociclib and G1T48 hit the market.
01/23/19
JPMS
01/23/19
DOWNGRADE
Target $41
JPMS
Neutral
JPMorgan downgrades G1 Therapeutics with lack of first half catalysts
JPMorgan analyst Anupam Rama downgraded G1 Therapeutics to Neutral from Overweight and cut his price target for the shares to $41 from $59. The downgrade is largely dictated by key clinical data being weighted towards the second half of 2019, Rama tells investors in a research note. As such, he sees the stock's catalysts more in the summer / second half of the year timeframe.
01/23/19
JPMS
01/23/19
DOWNGRADE
Target $41
JPMS
Neutral
G1 Therapeutics downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Anupam Rama downgraded G1 Therapeutics to Neutral and lowered his price target for the shares to $41 from $59. The analyst made a host of rating changes in the smid cap Biotech space following his firm's Healthcare Conference.
02/07/19
RILY
02/07/19
INITIATION
Target $55
RILY
Buy
G1 Therapeutics initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Harshita Polishetty started G1 Therapeutics with a Buy rating and $55 price target.
AMGN Amgen
$168.36

-1.5 (-0.88%)

04/10/19
JEFF
04/10/19
NO CHANGE
Target $230
JEFF
Buy
Amgen has $500M drug with Evenity despite box warning, says Jefferies
Jefferies analyst Michael Yee says that despite the inclusion of a boxed warning highlighting the potential increased cardiovascular risk, Evenity is an incremental $500M-plus drug for Amgen. The analyst points out that Forteo did $1.5B despite a warning label for bone cancer. He keeps a Buy rating on Amgen with a $230 price target.
05/16/19
COWN
05/16/19
NO CHANGE
COWN
Outperform
Amgen early data for AMG 510 'looks strong,' says Cowen
Cowen analyst Yaron Werber said the initial data in ASCO abstract for Amgen's AMG 510 "looks strong" in lung cancer patients and was better than he anticipated. The data, while still early, suggest AMG 510 is a promising therapy for a "sizable" $2B-$2.5B market, Werber tells investors. He maintains an Outperform rating on Amgen shares.
05/20/19
FBCO
05/20/19
INITIATION
Target $208
FBCO
Outperform
Amgen initiated with an Outperform at Credit Suisse
Credit Suisse analyst Evan Seigerman initiated Amgen with an Outperform rating and a price target of $208, saying the stock is "attractive" relative to its peers because of its "underappreciated" biosimilars assets that may offset the expected revenue decline in its core business. The analyst is also positive on Amgen's promising pipeline that includes oncology and immunology assets along with its discounted valuation, noting that the stock is currently trading at 12.1-times expected forward earnings vs. 17.7-times for the S&P500 and 14.4-times or more for its major pharma peers.
EXAS Exact Sciences
$96.03

-0.14 (-0.15%)

05/01/19
ADAM
05/01/19
NO CHANGE
Target $110
ADAM
Buy
Exact Sciences price target raised to $110 from $100 at Canaccord
Canaccord analyst Mark Massaro raised his price target for Exact Sciences (EXAS) to $110 from $100 and maintained a Buy rating after the company's Q1 beat and guide for Q2 revenue and volumes above consensus. In a research note to investors, Massaro says he is "impressed" at the strong demand that the joint Pfizer (PFE) and Exact reps are stirring up in the field, coupled with refinements both are making to maximize its impact. Exact seems to be getting better and better and remains among the elite growth companies in Massaro's sector, adding that Exact remains one of his top picks for 2019. He views 2019 raised guidance as beatable, which sets the stock up for further gains this year.
05/01/19
JEFF
05/01/19
NO CHANGE
Target $115
JEFF
Buy
Exact Sciences price target raised to $115 from $100 at Jefferies
Jefferies analyst Brandon Couillard raised his price target for Exact Sciences (EXAS) to $115 from $100 saying the company's Q1 showed "good progress on multiple fronts." Exact's momentum with Pfizer (PFE) is building, its penetration into a $15B-$20B total addressable market is "still tiny" at 4.6%, and its pipeline is progressing well, Couillard tells investors in a research note. He reiterates a Buy rating on the shares.
05/01/19
BTIG
05/01/19
NO CHANGE
Target $130
BTIG
Buy
Exact Sciences price target raised to $130 from $110 at BTIG
BTIG analyst Sean Lavin raised his price target on Exact Sciences to $130 and kept his Buy rating after its Q1 revenue beat and a raise in FY19 outlook. The analyst notes that with nearly all metrics outperforming in the quarter, he sees "little risk to the current momentum", and believes that the management's marketing / salesforce ramps should continue to be productive and lead to beats throughout the year.
05/01/19
CHLM
05/01/19
NO CHANGE
Target $115
CHLM
Buy
Exact Sciences price target raised to $115 from $95 at Craig-Hallum
Craig-Hallum analyst Per Ostlund raised his price target for Exact Sciences to $115 from $95 saying that while Q1 is typically thought of as a seasonally challenged quarter sequentially, the company blew past Cologuard volume guidance and raised its 2019 outlook. The analyst reiterates a Buy rating on the shares.
BMY Bristol-Myers
$46.29

-0.55 (-1.17%)

05/20/19
05/20/19
DOWNGRADE

Hold
Bristol-Myers downgraded to Hold from Buy at Argus
As previously reported, Argus analyst David Toung downgraded Bristol-Myers (BMY) to Hold from Buy, saying he has "serious concerns" about the company's growth prospects after its announced acquisition of Celgene (CELG). The analyst contends that Celgene's pipeline is not sufficient to offset the expected decline in revenues from its Revlimid, which will lose exclusivity in 2026. Toung adds that Bristol-Myers' "patent cliff" is also notable with loss of exclusivity expected for Opdivo in 2028, Eliquis in 2026, and Orencia in 2021. While the stock trades at 10.5-times forward earnings multiple - a discount to the 12-times peer group average - the analyst believes the valuation is appropriate.
05/20/19
ARGS
05/20/19
DOWNGRADE
ARGS
Hold
Bristol-Myers downgraded to Hold from Buy at Argus
Argus analyst David Toung downgraded Bristol-Myers to Hold from Buy.
05/03/19
JPMS
05/03/19
INITIATION
Target $62
JPMS
Overweight
Bristol-Myers reinstated with an Overweight at JPMorgan
Following a period of restriction, JPMorgan analyst Chris Schott reinstated coverage of Bristol-Myers Squibb (BMY) with an Overweight rating and $62 price target. The analyst had an Overweight rating on the shares and price target of $70 prior to restriction. While the company's proposed acquisition of Celgene (CELG) has been controversial, the shares are "too inexpensive to ignore," Schott tells investors in a research note. He sees the combined company generating 2020 earnings of $6.50 per share and 3% sales/6% earnings growth off of this base through 2025.
05/03/19
LEHM
05/03/19
DOWNGRADE
Target $102
LEHM
Equal Weight
Celgene downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoffrey Meacham downgraded Celgene (CELG) to Equal Weight from Overweight to reflect his increased confidence that the takeover by Bristol-Myers (BMY) will close. The analyst, who upgraded Bristol-Myers this morning to Overweight, says his thesis on Celgene has played out. He keeps a $102 price target for the shares.
DGX Quest Diagnostics
$97.08

-0.16 (-0.16%)

05/20/19
MZHO
05/20/19
NO CHANGE
Target $174
MZHO
Neutral
LabCorp price target raised to $174 from $150 at Mizuho
Mizuho analyst Ann Hynes raised her price target for Neutral-rated LabCorp (LH) to $174 from $150 and for Buy-rated Quest Diagnostics (DGX) to $110 from $106. Despite the recent outperformance in the group, both stocks will continue to re-rate higher as investors anticipate the long-term upside potential from UnitedHealth (UNH) lab initiatives, Hynes tells investors in a research note. The analyst thinks UnitedHealth's initiatives to form a preferred lab network and focus on out-of-network lab spend will bring greater pricing transparency to the clinical lab industry. She sees both LabCorp and Quest benefiting over time.
04/30/19
PIPR
04/30/19
NO CHANGE
PIPR
Overweight
Piper says LabCorp may be taking incremental volume from regional payers
After LabCorp (LH) reported a mixed Q1, with better than expected earnings and lower than expected revenue, Piper Jaffray analyst William Quirk said he found it interesting that management noted volumes from UnitedHealth (UNH) and CVS Health's (CVS) Aetna is stable after the initial decline in January. He thinks this implies that LabCorp and Quest (DGX) are likely taking some incremental volume from regional payers, adding that this is sooner than he anticipated following the new managed care deals. However, management "remains coy" about the future impact from other volume consolidating programs, such as UnitedHealth's Preferred Lab Network, according to Quirk. He keeps an Overweight rating on LabCorp shares.
04/24/19
SBSH
04/24/19
NO CHANGE
Target $102
SBSH
Neutral
Quest Diagnostics price target raised to $102 from $93 at Citi
Citi analyst Ralph Giacobbe raised his price target for Quest Diagnostics to $102 from $93 saying the company's Q1 results are encouraging as volumes are beginning to ramp. His new price target reflects the upside in the quarter and greater comfort in Quest hitting its guidance. Giacobbe keeps a Neutral rating on the shares.
04/24/19
ADAM
04/24/19
NO CHANGE
Target $103
ADAM
Buy
Quest Diagnostics price target raised to $103 from $97 at Canaccord
Canaccord analyst Mark Massaro raised his price target for Quest Diagnostics (DGX) to $103 from $97 and reiterated a Buy rating after the company delivered a "solid" Q1 top and bottom line beat, driven by stronger volume growth than the Street anticipated. Quest is off to a "good start" as it adds new volume growth related to 43M new lives from recent health plan wins from UnitedHealthcare (UNH) and others, and Quest expects volumes to gradually grow throughout this year, Massaro tells investors in a research note.

TODAY'S FREE FLY STORIES

QSR

Restaurant Brands

$70.30

0.295 (0.42%)

08:09
06/25/19
06/25
08:09
06/25/19
08:09
Initiation
Restaurant Brands initiated  »

Credit Suisse bullish on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUM

Humana

$267.20

-3.19 (-1.18%)

08:08
06/25/19
06/25
08:08
06/25/19
08:08
Hot Stocks
Humana enters collaboration with Aspen RxHealth »

Aspen RxHealth announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 13

    Nov

ACLS

Axcelis

$14.32

-0.18 (-1.24%)

08:08
06/25/19
06/25
08:08
06/25/19
08:08
Hot Stocks
Axcelis awarded first order for new Purion XE Power Series implanter »

Axcelis Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 10

    Jul

  • 07

    Aug

PHG

Philips

$42.92

-0.18 (-0.42%)

08:07
06/25/19
06/25
08:07
06/25/19
08:07
Hot Stocks
Philips enters collaboration with BioBright »

BioBright announced an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTCH

Match Group

$71.45

4.64 (6.95%)

08:07
06/25/19
06/25
08:07
06/25/19
08:07
Recommendations
Match Group analyst commentary  »

Jefferies sees 'no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSAT

ViaSat

$82.88

-0.59 (-0.71%)

, TDY

Teledyne

$266.52

1.625 (0.61%)

08:06
06/25/19
06/25
08:06
06/25/19
08:06
Hot Stocks
ViaSat and Teledyne Controls announce partnership »

Viasat (VSAT) and…

VSAT

ViaSat

$82.88

-0.59 (-0.71%)

TDY

Teledyne

$266.52

1.625 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DNKN

Dunkin' Brands

$81.01

1.47 (1.85%)

08:06
06/25/19
06/25
08:06
06/25/19
08:06
Initiation
Dunkin' Brands initiated  »

Credit Suisse sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

TROV

Trovagene

$2.57

0.045 (1.78%)

08:05
06/25/19
06/25
08:05
06/25/19
08:05
Syndicate
Breaking Syndicate news story on Trovagene »

Trovagene files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

HALO

Halozyme

$16.11

-0.34 (-2.07%)

08:04
06/25/19
06/25
08:04
06/25/19
08:04
Hot Stocks
Halozyme announces CRADA with VRC for use of ENHANZE technology »

Halozyme Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBM

Cambrex

$44.20

-0.01 (-0.02%)

, CMD

Cantel Medical

$75.43

-0.75 (-0.98%)

08:04
06/25/19
06/25
08:04
06/25/19
08:04
Hot Stocks
Cambrex appoints Dottie Donnelly-Brienza CHRO »

Cambrex (CBM) announced…

CBM

Cambrex

$44.20

-0.01 (-0.02%)

CMD

Cantel Medical

$75.43

-0.75 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

MET

MetLife

$49.09

0.17 (0.35%)

08:04
06/25/19
06/25
08:04
06/25/19
08:04
Periodicals
MetLife in talks to sell Hong Kong insurance unit to FWD, Bloomberg reports »

MetLife is in advanced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NANO

Nanometrics

$34.31

0.51 (1.51%)

, RTEC

Rudolph Technologies

$27.43

2.42 (9.68%)

08:03
06/25/19
06/25
08:03
06/25/19
08:03
Recommendations
Nanometrics, Rudolph Technologies analyst commentary  »

Nanometrics deal for…

NANO

Nanometrics

$34.31

0.51 (1.51%)

RTEC

Rudolph Technologies

$27.43

2.42 (9.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

  • 10

    Jul

GRUB

GrubHub

$72.05

0.91 (1.28%)

08:02
06/25/19
06/25
08:02
06/25/19
08:02
Periodicals
GrubHub repays NYC restaurant $10,000 over fee protest, NY Post reports »

GrubHub repaid an unnamed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 09

    Jul

ATNM

Actinium Pharmaceuticals

$0.26

0.0003 (0.12%)

08:02
06/25/19
06/25
08:02
06/25/19
08:02
Hot Stocks
Actinium Pharma announces results from ACT program »

Actinium Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SITE

SiteOne Landscape

$66.97

-0.25 (-0.37%)

07:57
06/25/19
06/25
07:57
06/25/19
07:57
Upgrade
SiteOne Landscape rating change  »

SiteOne Landscape…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKRX

Akorn

$4.71

-0.06 (-1.26%)

07:55
06/25/19
06/25
07:55
06/25/19
07:55
Hot Stocks
Breaking Hot Stocks news story on Akorn 

Akorn trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:55
06/25/19
06/25
07:55
06/25/19
07:55
General news
U.S. chain store sales rose another 2.7% in the week ended June 22 »

U.S. chain store sales…

GERN

Geron

$1.52

0.04 (2.70%)

07:55
06/25/19
06/25
07:55
06/25/19
07:55
Conference/Events
Geron to hold a Key Opinion Leader Event »

CEO Scarlett and CFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

CZR

Caesars

$11.43

1.44 (14.41%)

, ERI

Eldorado Resorts

$45.86

-5.36 (-10.46%)

07:54
06/25/19
06/25
07:54
06/25/19
07:54
Downgrade
Caesars, Eldorado Resorts rating change  »

Caesars downgraded to…

CZR

Caesars

$11.43

1.44 (14.41%)

ERI

Eldorado Resorts

$45.86

-5.36 (-10.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 02

    Jul

BHF

Brighthouse Financial

$38.10

-0.01 (-0.03%)

07:52
06/25/19
06/25
07:52
06/25/19
07:52
Downgrade
Brighthouse Financial rating change  »

Brighthouse Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCMI

PCM, Inc.

$34.89

10.54 (43.29%)

, NSIT

Insight Enterprises

$55.92

-0.27 (-0.48%)

07:50
06/25/19
06/25
07:50
06/25/19
07:50
Downgrade
PCM, Inc., Insight Enterprises rating change  »

PCM, Inc. downgraded to…

PCMI

PCM, Inc.

$34.89

10.54 (43.29%)

NSIT

Insight Enterprises

$55.92

-0.27 (-0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ERI

Eldorado Resorts

$45.86

-5.36 (-10.46%)

, CZR

Caesars

$11.43

1.44 (14.41%)

07:50
06/25/19
06/25
07:50
06/25/19
07:50
Upgrade
Eldorado Resorts, Caesars rating change  »

Eldorado Resorts upgraded…

ERI

Eldorado Resorts

$45.86

-5.36 (-10.46%)

CZR

Caesars

$11.43

1.44 (14.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 02

    Jul

07:50
06/25/19
06/25
07:50
06/25/19
07:50
General news
Oil Action: WTI crude »

Oil Action: WTI crude…

CSCO

Cisco

$57.20

0.17 (0.30%)

07:49
06/25/19
06/25
07:49
06/25/19
07:49
Recommendations
Cisco analyst commentary  »

Cisco remains our…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jul

  • 14

    Aug

JEC

Jacobs Engineering

$81.91

-0.47 (-0.57%)

07:47
06/25/19
06/25
07:47
06/25/19
07:47
Hot Stocks
Jacobs Engineering selected by Sepco for maritime project in Saudi Arabia »

Jacobs has been selected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.